




>>Entry Name: **Raclopride**, BAN, INN

Synonym(s): 3,5-Dichloro-*N*-[(1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxy-6-methoxybenzamide, 9Cl. 3,5-Dichloro-*N*-(1-ethylpyrrolidin-2-ylmethyl)-6-methoxysalicylamide, 8Cl. *N*-Ethyl-2-(3,5-dichloro-6-hydroxy-2-methoxybenzamidomethyl)pyrrolidine



Related CAS Registry Numbers(s): 97849-54-2 98527-07-2 98527-08-3 98527-32-3 99764-45-1 109920-92-5 114805-08-2 143615-54-7

Molecular Formula: C₁₅H₂₀Cl₂N₂O₃

Molecular Weight: 347.24

Accurate Mass: 346.085097

Percentage Composition: C 51.88%; H 5.81%; Cl 20.42%; N 8.07%; O 13.82%

Use/Importance: Dopamine D₂-receptor antagonist, antipsychotic agent

Calculated Log P Data: Log P 4.11 (calc)

Other Data: C-11 labelled compd. used as a radiopharmaceutical agent (C-11 Raclopride, USAN)

>>Variant: (*S*)-form

Synonym(s): FLA 870

CAS Registry Number: 84225-95-6

Molecular Formula: C₁₅H₂₀Cl₂N₂O₃

Molecular Weight: 347.24

Accurate Mass: 346.085097

Percentage Composition: C 51.88%; H 5.81%; Cl 20.42%; N 8.07%; O 13.82%

Physical Description: Cryst. (isooctane)

Melting Point: Mp 48-49°

Optical Rotation: [α]_D²⁵ -64 (c, 1.26 in CHCl₃)

Calculated Log P Data: Log P 1.22 (calc)

Other Data: Pharmacol. active enantiomer

Sigma: R5136

>>Derivative: Tartrate (1:1)

Synonym(s): Raclopride tartrate, USAN. A 40664

CAS Registry Number: 98185-20-7

Physical Description: Cryst. (EtOH)

Melting Point: Mp 142-143°

Optical Rotation: [α]_D²⁰ -64 (c, 2 in Me₂CO)

>>Derivative: Phosphate

Physical Description: Cryst. (EtOH)

Melting Point: Mp 148-149°

References:

- Eur. Pat.*, 1982, *Astra Lakemedel*, 60 235; *CA*, **98**, 53687j, (*synth*)
Koehler, C. *et al.*, *Biochem. Pharmacol.*, 1985, **34**, 2251, (*pharmacol*)
Farde, L. *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 1985, **82**, 3863-3867, (*C-11 raclopride, synth, metab, use*)
De Paulis, T. *et al.*, *J. Med. Chem.*, 1986, **29**, 61, (*synth, isomers, cmr*)
Oegren, S.O. *et al.*, *Psychopharmacology*, 1986, **90**, 287
Ehrin, E. *et al.*, *J. Labelled Compd. Radiopharm.*, 1987, **24**, 931, (*synth*)
Hoegberg, T. *et al.*, *J. Pharm. Pharmacol.*, 1987, **39**, 787, (*cryst struct, pharmacol*)
Hall, H. *et al.*, *Psychopharmacol. Ser.*, 1989, **7**, 123, (*pharmacol, exp, rev*)
Lannoye, G.S. *et al.*, *J. Med. Chem.*, 1990, **33**, 2430, (*synth, sar*)
Hoegberg, T., *Drugs of the Future*, 1991, **16**, 333, (*rev*)
Karlsson, A. *et al.*, *Chirality*, 1992, **4**, 323, (*chromatog*)
Lewander, T. *et al.*, *Novel Antipsychotic Drugs*, (ed. Meltzer, H.Y.), Raven, 1992, 67, (*rev*)
Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 614
Logan, J. *et al.*, *J. Cereb. Blood Flow Metab.*, 1994, **14**, 995-1010, (*C-11 raclopride*)